{Reference Type}: Journal Article
{Title}: First in-human evaluation of [1-13C]pyruvate in D2O for hyperpolarized MRI of the brain: A safety and feasibility study.
{Author}: Deh K;Zhang G;Park AH;Cunningham CH;Bragagnolo ND;Lyashchenko S;Ahmmed S;Leftin A;Coffee E;Hricak H;Miloushev V;Mayerhoefer M;Keshari KR;
{Journal}: Magn Reson Med
{Volume}: 91
{Issue}: 6
{Year}: 2024 Jun 11
{Factor}: 3.737
{DOI}: 10.1002/mrm.30002
{Abstract}: <B>OBJECTIVE: </B>To investigate the safety and value of hyperpolarized (HP) MRI of [1-13C]pyruvate in healthy volunteers using deuterium oxide (D2O) as a solvent.<BR><B>METHODS: </B>Healthy volunteers (n = 5), were injected with HP [1-13C]pyruvate dissolved in D2O and imaged with a metabolite-specific 3D dual-echo dynamic EPI sequence at 3T at one site (Site 1). Volunteers were monitored following the procedure to assess safety. Image characteristics, including SNR, were compared to data acquired in a separate cohort using water as a solvent (n = 5) at another site (Site 2). The apparent spin-lattice relaxation time (T1) of [1-13C]pyruvate was determined both in vitro and in vivo from a mono-exponential fit to the image intensity at each time point of our dynamic data.<BR><B>RESULTS: </B>All volunteers completed the study safely and reported no adverse effects. The use of D2O increased the T1 of [1-13C]pyruvate from 66.5 ± 1.6 s to 92.1 ± 5.1 s in vitro, which resulted in an increase in signal by a factor of 1.46 ± 0.03 at the time of injection (90 s after dissolution). The use of D2O also increased the apparent relaxation time of [1-13C]pyruvate by a factor of 1.4 ± 0.2 in vivo. After adjusting for inter-site SNR differences, the use of D2O was shown to increase image SNR by a factor of 2.6 ± 0.2 in humans.<BR><B>CONCLUSIONS: </B>HP [1-13C]pyruvate in D2O is safe for human imaging and provides an increase in T1 and SNR that may improve image quality.